Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties

Journal of Clinical Oncology

Volumn 19, Issue 11, 2001, Pages 2937-2947

  Tolcher, A W ^a   Eckhardt, S G ^a   Kuhn, J ^a   Hammond, L ^a   Weiss, G ^a   Rizzo, J ^a   Aylesworth, C ^a   Hidalgo, M ^a   Patnaik, A ^a   Schwartz, G ^a   Felton, S ^a   Campbell, E ^a   Rowinsky, E K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); DNA TOPOISOMERASE INHIBITOR; REBECCAMYCIN; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER THERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG STRUCTURE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0035366329     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.11.2937     Document Type: Article

References (19)

1. Production and biological activity of rebeccamycin: A novel antitumor agent
2. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group
3. Structure-activity relationships in a series of substituted indolocarbazoles: Topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties
4. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle
5. Fluorescence polarization studies of the binding of BMS 181176 to DNA
6. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin
7. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin
8. In vitro antitumor activity of rebeccamycin analog (NSC: 655649) against pediatric solid tumors
9. Phase I clinical and pharmacologic study of a rebeccamycin analog (NSC 655649)
10. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
11. DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells
12. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
13. Cleavage of DNA by mammalian DNA topoisomerase II
14. Relation of preclinical toxicology to findings in early clinical trials
15. LC/MS identification of a rebeccamycin analog metabolite
16. A trial of rebeccamycin analogue (NSC 655649) in children with solid tumors: A pediatric oncology group phase I cooperative agreement study
17. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
18. Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit